Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model

Che, Huilian; Bae, In-Ho; Lim, Kyung Seob; Song, In Taek; Lee, Haeshin; Muthiah, Muthunarayanan; Namgung, Ran; Kim, Won Jong; Kim, Dong-Gon; Ahn, Youngkeun; Cho, Jeong Gwan; Park, In Kyu

doi:10.1016/j.biomaterials.2012.07.045

Cited by 52 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both activation of proliferative signals and inhibition of death processes, which lead to survival, have been reported in several vascular proliferative diseases (i.e. atherosclerosis, post-angioplasty restenosis and vein graft disease) including PAH [11,12,[28][29][30][31]. However, pulmonary vascular remodelling is an active process of structural change intrinsically linked to modification in cell growth, cell death, cell migration, cell differentiation, and the synthesis or degradation of extracellular matrix.…”

Section: Hallmarksmentioning

confidence: 99%

Pathogenesis of pulmonary arterial hypertension: lessons from cancer

et al. 2013

View full text Add to dashboard Cite

Although the causal pathomechanisms contributing to remodelling of the pulmonary vascular bed in pulmonary arterial hypertension (PAH) are still unclear, several analogous features with carcinogenesis have led to the emergence of the cancer-like concept. The major similarities concern the altered crosstalk between cells from different tissue types, unexplained proliferation and survival of pulmonary smooth muscle and endothelial cells, the metabolic (glycolytic) shifts, and the association with the immune system. However, major differences between PAH and cancer exist, including the absence of invasion and metastasis, as well as the pathogenic genes involved and the degrees of angiogenesis impairment and genetic instability. It is clear that PAH is not a cancer, but this cancer-like concept has opened a new field of investigation and raises the possibility that antiproliferative and/or oncological drugs may exert therapeutic effects not only in cancer, but also in PAH. Such analogies and differences are discussed here. @ERSpublications Intriguing analogies between PAH pathogenesis and carcinogenesis are observed, but crucial differences also exist

show abstract

Section: Hallmarksmentioning

confidence: 99%

Pathogenesis of pulmonary arterial hypertension: lessons from cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Ра-нее были установлены активация Akt1 во время созревания неоинтимы [18] и антирестенозная эффективность ингибирования Akt1 [19]. В недав-них исследованиях Che и коллеги [20] применили методы координационной химии для достижения стабильного прикрепления дофамин-конъюгиро-ванной гиалуроновой кислоты на стенты с помо-щью связей, образованных между дофаминовыми остатками и ионами металлов на поверхности стента. Дополнительно такие стенты были моди-фицированы полиплексами из коротких интерфе-рирующих РНК (миРНК), Akt1 и поперечно сши-того дисульфидными связями PEI.…”

Section: гены ингибирующие пролиферацию и миграцию гладкомышечных клunclassified

“…Замедленное высвобождение миРНК с поверхности стента на-блюдалось как минимум в течение 72 часов in situ. В исследовании in vivo стенты с Akt1 и миРНК, имплантированные в кроличьи подвздошные ар-терии, уменьшали степень внутристентового ре-стеноза на 50 % через 4 недели после развертыва-ния по сравнению с НМС [20].…”

Section: гены ингибирующие пролиферацию и миграцию гладкомышечных клunclassified

Achievements and Prospects in the Field of Gene-Eluting Coronary Stents

Фаттахов¹,

Куликов²,

Литвинова³

2016

Kompleks. probl. serdečno-sosud. zabol.

View full text Add to dashboard Cite

1 Федеральное государственное автономное образовательное учреждение высшего образования «Балтийский федеральный университет имени Иммануила Канта». Калининград, Россия 2 Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет им. И. И. Мечникова». Санкт-Петербург, Россия В настоящем обзоре систематизированы основные современные разработки и достижения в области ген-выделяющих стен-тов; обсуждены их преимущества и недостатки как потенциальной альтернативы непокрытым металлическим стентам и стентам, выделяющим лекарства. Рассмотрены основные стратегии оптимизации, необходимые для перевода основанных на применении ген-выделяющих стентов технологий из экспериментальной сферы в клиническую медицину.Ключевые слова: ген-выделяющий стент, ген, рестеноз, вектор, ишемическая болезнь сердца, чрескожное коронарное вме-шательство. In this paper, we summarize the main recent developments and achievements in the field of gene-eluting stents, their advantages and disadvantages as a potential alternative to the bare metal stents and drug-eluting stents are discussed. the basic optimization strategies required for the translation of technologies based on the use of gene-eluting stents from experimental sphere to clinical medicine are examined. ACHIEVEMENTS AND PROSPECTS IN THE FIELD OF GENE-ELUTING CORONARY STENTS

show abstract

“…For example, a wide range of therapeutic DNA and viruses were delivered from the stent surface to reduce the extent of restenosis. [5][6][7] The above studies have all used polymer-coated stents to elute the genes. This polymer component, however, has been shown to cause local inflammatory responses and late thrombosis.…”

Section: Introductionmentioning

confidence: 99%

Anchoring of self-assembled plasmid DNA/ anti-DNA antibody/cationic lipid micelles on bisphosphonate-modified stent for cardiovascular gene delivery

Ma¹,

Wang²,

Fishbein³

et al. 2013

IJN

View full text Add to dashboard Cite

Purpose:To investigate the anchoring of plasmid DNA/anti-DNA antibody/cationic lipid tri-complex (DAC micelles) onto bisphosphonate-modified 316 L coronary stents for cardiovascular site-specific gene delivery. Methods: Stents were first modified with polyallylamine bisphosphonate (PAA-BP), thereby enabling the retention of a PAA-BP molecular monolayer that permits the anchoring (via vector-binding molecules) of DAC micelles. DAC micelles were then chemically linked onto the PAA-BP-modified stents by using N-succinimidyl-3-(2-pyridyldithiol)-propionate (SPDP) as a crosslinker. Rhodamine-labeled DNA was used to assess the anchoring of DAC micelles, and radioactive-labeled antibody was used to evaluate binding capacity and stability. DAC micelles (encoding green fluorescent protein) were tethered onto the PAA-BP-modified stents, which were assessed in cell culture. The presence of a PAA-BP molecular monolayer on the steel surface was confirmed by X-ray photoelectron spectroscopy and atomic force microscope analysis. Results: The anchoring of DAC micelles was generally uniform and devoid of large-scale patches of defects. Isotopic quantification confirmed that the amount of antibody chemically linked on the stents was 17-fold higher than that of the physical adsorbed control stents and its retention time was also significantly longer. In cell culture, numerous green fluorescent protein-positive cells were found on the PAA-BP modified stents, which demonstrated high localization and efficiency of gene delivery. Conclusion:The DAC micelle-immobilized PAA-BP-modified stents were successful as a gene delivery system. Gene delivery using DAC micelle-tethered stent-based PAA-BP functionalization should be suitable for a wide array of single or multiple therapeutic gene strategies, and could be used on cardiovascular metallic implants for achieving efficient gene therapy.

show abstract

Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model

Cited by 52 publications

References 23 publications

Pathogenesis of pulmonary arterial hypertension: lessons from cancer

Pathogenesis of pulmonary arterial hypertension: lessons from cancer

Achievements and Prospects in the Field of Gene-Eluting Coronary Stents

Anchoring of self-assembled plasmid DNA/ anti-DNA antibody/cationic lipid micelles on bisphosphonate-modified stent for cardiovascular gene delivery

Contact Info

Product

Resources

About